title: Good outcomes of patients with stage IB endometrial cancer with surgery alone.
abstract: BACKGROUND
  Most patients with endometrial cancer have stage I disease. Adjuvant therapy in stage IB (formerly IC) endometrial cancer is controversial, treatment options including observation or brachytherapy/ radiotherapy in grade 1-3 patients with or without chemotherapy. The purpose of this study was to assess the outcomes of our patients with stage IB endometrioid endometrial cancer.
  
  
  METHODS
  Sixty two patients with stage IB endometrial cancer and endometrioid histology were retrospectively evaluated. All patients were initially treated surgically by the same surgeon with comprehensive staging, i.e. total abdominal hysterectomy, bilateral salphingooopherectomy, bilateral pelvic and paraaortic lymph node dissection and omentectomy. Adjuvant radiotherapy was discussed with patients and utilized by those who accepted. Adjuvant chemotherapy was not given to any of the patients.
  
  
  RESULTS
  Median age was 62 (range, 42-95). Ninety percent of the patients had grade 1-2 disease. Thirteen patients (21%) received intra vaginal brachytherapy (IVBT) and one received whole pelvic radiotherapy (WPRT). Median follow-up time was 46 months (range, 9-77 months). Three patients experienced recurrence (4.8%), two of them died on follow-up and one was still alive at last visit. Two patients with recurrence had FIGO grade 2 tumors and one had a grade 3 tumor. Two patients (3.2%) died without evidence of recurrent disease. Relapse free survival at 5 years was 94.4% and overall survival was 93.1%.
  
  
  CONCLUSIONS
  Patients with stage IB disease in our study demonstrated relatively low recurrence rates although the majority of them received no adjuvant treatment. Surgery alone may be sufficient for most patients with this stage of endometrial cancer.
authors.affiliation: Department of Medical Oncology, Baskent University Hospital, Ankara, Turkey E-mail : samedrahatli@hotmail.com.
authors.forename: Samed
authors.initials: S
authors.lastname: Rahatli
authors.forename: Omer
authors.initials: O
authors.lastname: Dizdar
authors.forename: Nadire
authors.initials: N
authors.lastname: Kucukoztas
authors.forename: Arzu
authors.initials: A
authors.lastname: Oguz
authors.forename: Selim
authors.initials: S
authors.lastname: Yalcin
authors.forename: Ozlem
authors.initials: O
authors.lastname: Ozen
authors.forename: Nihan Haberal
authors.initials: NH
authors.lastname: Reyhan
authors.forename: Cagla
authors.initials: C
authors.lastname: Tarhan
authors.forename: Ferah
authors.initials: F
authors.lastname: Yildiz
authors.forename: Polat
authors.initials: P
authors.lastname: Dursun
authors.forename: Ozden
authors.initials: O
authors.lastname: Altundag
authors.forename: Ali
authors.initials: A
authors.lastname: Ayhan
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy / Q000379:methods*; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D016889:Endometrial Neoplasms / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery*; D005260:Female; D006801:Humans; D007044:Hysterectomy; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D010052:Ovariectomy; D012189:Retrospective Studies; D058994:Salpingectomy; D016896:Treatment Outcome